



### Company profile

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary ion channel platform technologies, ionX and MultiCore, to discover and develop a deep pipeline of best and first in class novel drug candidates focused on the treatment of serious ion-channel targeted central nervous system disorders.

Bionomics' lead drug candidate BNC210, a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, met both primary endpoints from its Phase 2 trial in generalised anxiety disorder and Bionomics is currently awaiting results in a Phase 2 trial for the treatment of Post-traumatic Stress Disorder and a Phase 2 trial for treatment of Agitation in the Elderly. Bionomics has a robust pipeline of first-in-class ion channel programs.

Bionomics has a strategic partnership with Merck and Co., Inc (known as MSD outside the United States and Canada). A cognition therapeutic candidate entered clinical development and triggered US\$10M milestone payment in a deal valued up to US\$506M in upfront, research and milestone payments plus additional royalties on net sales of licensed drugs. Merck & Co. also has an equity investment in Bionomics.

### Speaker Profile

Mr Steven Lydeamore, Chief Financial Officer, Bionomics Limited



Mr Lydeamore is a Certified Practising Accountant with 26 years' international pharmaceutical experience. He has senior executive experience spanning Asia Pacific, Europe, Latin America and North America in finance, business development, mergers and acquisitions, sales and marketing, manufacturing and research and development.

Mr Lydeamore worked in various finance roles for F.H. Faulding & Co. Limited in Australia over a ten year period followed by four years in the United States at Mayne Pharma (USA) Limited.

For the eleven years prior to joining Bionomics, Mr Lydeamore worked for Apotex Inc., the largest Canadian-owned pharmaceutical company, most recently as President, Apobiologix. Mr Lydeamore holds a Bachelor of Business (Applied Economics) (Deakin) and a



Master of Business Administration (RMIT). He is a member of CPA Australia, Australian Institute of Company Directors and Licensing Executives Society (U.S.A. and Canada), Inc. and a Graduate of the Australian Institute of Company Directors.